WO2000031238A3 - Methods and reagents for increasing proliferative capacity and preventing replicative senescence - Google Patents
Methods and reagents for increasing proliferative capacity and preventing replicative senescence Download PDFInfo
- Publication number
- WO2000031238A3 WO2000031238A3 PCT/US1999/027907 US9927907W WO0031238A3 WO 2000031238 A3 WO2000031238 A3 WO 2000031238A3 US 9927907 W US9927907 W US 9927907W WO 0031238 A3 WO0031238 A3 WO 0031238A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reagents
- methods
- proliferative capacity
- replicative senescence
- increasing proliferative
- Prior art date
Links
- 239000003153 chemical reaction reagent Substances 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title 1
- 230000008943 replicative senescence Effects 0.000 title 1
- 230000037361 pathway Effects 0.000 abstract 2
- 108010017842 Telomerase Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000000394 mitotic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL14332899A IL143328A0 (en) | 1998-11-25 | 1999-11-24 | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
CA002352486A CA2352486A1 (en) | 1998-11-25 | 1999-11-24 | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
AU21566/00A AU2156600A (en) | 1998-11-25 | 1999-11-24 | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
JP2000584049A JP2002530436A (en) | 1998-11-25 | 1999-11-24 | Method and reagent for enhancing proliferation ability and preventing replication senescence |
EP99965890A EP1133552A2 (en) | 1998-11-25 | 1999-11-24 | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10989198P | 1998-11-25 | 1998-11-25 | |
US12054999P | 1999-02-17 | 1999-02-17 | |
US60/120,549 | 1999-02-17 | ||
US60/109.891 | 1999-02-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000031238A2 WO2000031238A2 (en) | 2000-06-02 |
WO2000031238A3 true WO2000031238A3 (en) | 2000-11-09 |
Family
ID=26807479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/027907 WO2000031238A2 (en) | 1998-11-25 | 1999-11-24 | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1133552A2 (en) |
JP (1) | JP2002530436A (en) |
AU (1) | AU2156600A (en) |
CA (1) | CA2352486A1 (en) |
IL (1) | IL143328A0 (en) |
WO (1) | WO2000031238A2 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE556713T1 (en) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS P38 KINASE INHIBITORS |
EP1170378A1 (en) * | 2000-06-26 | 2002-01-09 | Boehringer Ingelheim International GmbH | Method for monitoring the effect of cancer therapies |
DE10054974A1 (en) * | 2000-11-06 | 2002-06-06 | Epigenomics Ag | Diagnosis of diseases associated with Cdk4 |
AU2002242854A1 (en) | 2001-03-21 | 2002-10-03 | Geron Corporation | Use of telomerase reverse transcriptase to create homozygous knockout animals |
US7262174B2 (en) | 2001-05-09 | 2007-08-28 | Geron Corporation | Treatment for wounds |
AU2003208580A1 (en) * | 2002-02-05 | 2003-09-02 | Technion Research And Development Foundation Ltd | Lineage committed stem cells selected for telomerase promoter activity |
AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
WO2004076483A1 (en) * | 2003-02-26 | 2004-09-10 | Japan Science And Technology Agency | Transcriptional factor inducing apoptosis in cancer cell |
PT1636585E (en) | 2003-05-20 | 2008-03-27 | Bayer Pharmaceuticals Corp | Diaryl ureas with kinase inhibiting activity |
DK1644009T3 (en) | 2003-06-23 | 2018-03-05 | Telomerase Activation Sciences Inc | Compositions for increasing telomerase activity and treating HIV infection |
US9248088B2 (en) | 2003-06-25 | 2016-02-02 | Telomerase Activation Sciences, Inc. | Compositions and methods for skin conditioning |
US8431123B2 (en) | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
US8710012B2 (en) | 2003-07-14 | 2014-04-29 | Cls Therapeutics Limited | Method for treating oncological diseases |
JP4777887B2 (en) | 2003-07-23 | 2011-09-21 | バイエル、ファーマシューテイカルズ、コーポレイション | Fluoro-substituted omegacarboxyaryl diphenylureas for the treatment and prevention of diseases and conditions |
JP4991547B2 (en) * | 2004-09-28 | 2012-08-01 | クアーク・ファーマスーティカルス、インコーポレイテッド | Oligoribonucleotides and methods of use thereof for the treatment of alopecia, acute renal failure and other diseases |
EP1880733A4 (en) | 2005-04-25 | 2009-08-12 | Genkin Dmitry Dmitrievich | Method for increasing longevity of a human being and animals |
JP2006325444A (en) * | 2005-05-24 | 2006-12-07 | Toyobo Co Ltd | Medium for cell proliferation |
EP1951881A4 (en) * | 2005-11-07 | 2009-03-11 | Gen Hospital Corp | Methods and compositions for modulation of stem cell aging |
JP5372769B2 (en) | 2006-11-28 | 2013-12-18 | シーエルエス セラピューティック リミティド | Method for treating human disease associated with increased amount of deoxyribonucleic acid in the extracellular space of tissue and pharmaceutical formulation for performing the method |
US8598150B1 (en) | 2008-04-02 | 2013-12-03 | Jonathan R. Brestoff | Composition and method for affecting obesity and related conditions |
US8987245B2 (en) | 2008-04-02 | 2015-03-24 | Jonathan R. Brestoff Parker | Composition and method for affecting obesity and related conditions |
CN106008707A (en) | 2009-03-09 | 2016-10-12 | 生物蛋白有限公司 | Mirac proteins |
PL2437606T3 (en) | 2009-05-18 | 2017-07-31 | Telomerase Activation Sciences, Inc. | Compositions and methods for increasing telomerase activity |
KR20130024888A (en) | 2010-02-16 | 2013-03-08 | 오슬로 유니버시티 하스피탈 에이치에프 | Polypeptides |
GB201202228D0 (en) * | 2012-02-08 | 2012-03-28 | Queen Mary & Westfield College | Reversal of replicative senescence |
US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
RU2726131C2 (en) | 2015-05-22 | 2020-07-09 | Дмитрий Дмитриевич Генкин | Extracellular dna as a therapeutic target in neurodegeneration |
CA3047140A1 (en) | 2017-01-09 | 2018-07-12 | Oisin Biotechnologies | Constructs for expression of therapeutic proteins in target cells |
AU2019209770A1 (en) | 2018-01-16 | 2020-09-03 | Cls Therapeutics Limited | Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity |
WO2019166702A1 (en) | 2018-02-28 | 2019-09-06 | Hagalife | Use of a flash irradiation method to increase longevity and/or to delay the effects of ageing in mammals |
US11603543B2 (en) | 2018-04-18 | 2023-03-14 | Oisin Biotechnologies, Inc. | Fusogenic lipid nanoparticles for target cell-specific production of a therapeutic protein |
CN113774020B (en) * | 2021-08-24 | 2023-04-14 | 河北朋和生物科技有限公司 | Construction method of adipose-derived mesenchymal stem cell bank |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0537008A1 (en) * | 1991-10-11 | 1993-04-14 | E.R. SQUIBB & SONS, INC. | Use of biphosphonates for the manufacture of a medicament for blocking neoplastic transformation of cells induced by ras oncogenes |
EP0618221A2 (en) * | 1993-04-02 | 1994-10-05 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of farnesyl protein transferase |
WO1996012820A1 (en) * | 1994-10-24 | 1996-05-02 | Cold Spring Harbor Laboratory | INTERACTIONS BETWEEN Raf PROTO-ONCOGENES AND CDC25 PHOSPHATASES, AND USES RELATED THERETO |
US5624936A (en) * | 1995-03-29 | 1997-04-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5721236A (en) * | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
WO1998037181A2 (en) * | 1997-02-20 | 1998-08-27 | Whitehead Institute For Biomedical Research | Telomerase catalytic subunit gene and encoded protein |
WO1999035243A2 (en) * | 1998-01-12 | 1999-07-15 | Cold Spring Harbor Laboratory | Extension of cellular lifespan, methods and reagents |
WO1999042578A2 (en) * | 1998-01-30 | 1999-08-26 | Cold Spring Harbor Laboratory | Modulation of cell proliferation, methods and reagents |
-
1999
- 1999-11-24 CA CA002352486A patent/CA2352486A1/en not_active Abandoned
- 1999-11-24 IL IL14332899A patent/IL143328A0/en unknown
- 1999-11-24 WO PCT/US1999/027907 patent/WO2000031238A2/en not_active Application Discontinuation
- 1999-11-24 JP JP2000584049A patent/JP2002530436A/en not_active Withdrawn
- 1999-11-24 EP EP99965890A patent/EP1133552A2/en not_active Withdrawn
- 1999-11-24 AU AU21566/00A patent/AU2156600A/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0537008A1 (en) * | 1991-10-11 | 1993-04-14 | E.R. SQUIBB & SONS, INC. | Use of biphosphonates for the manufacture of a medicament for blocking neoplastic transformation of cells induced by ras oncogenes |
EP0618221A2 (en) * | 1993-04-02 | 1994-10-05 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of farnesyl protein transferase |
US5721236A (en) * | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
WO1996012820A1 (en) * | 1994-10-24 | 1996-05-02 | Cold Spring Harbor Laboratory | INTERACTIONS BETWEEN Raf PROTO-ONCOGENES AND CDC25 PHOSPHATASES, AND USES RELATED THERETO |
US5624936A (en) * | 1995-03-29 | 1997-04-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1998037181A2 (en) * | 1997-02-20 | 1998-08-27 | Whitehead Institute For Biomedical Research | Telomerase catalytic subunit gene and encoded protein |
WO1999035243A2 (en) * | 1998-01-12 | 1999-07-15 | Cold Spring Harbor Laboratory | Extension of cellular lifespan, methods and reagents |
WO1999042578A2 (en) * | 1998-01-30 | 1999-08-26 | Cold Spring Harbor Laboratory | Modulation of cell proliferation, methods and reagents |
Non-Patent Citations (7)
Title |
---|
EILEEN M. ROGAN ET AL: "Alterations in p53 and p16INK4a Expression and Telomere Length during spontaneous Immortalization of Li-Fraumeni Syndrome Fibroblasts", MOLECULAR AND CELLULAR BIOLOGY, vol. 15, no. 9, September 1995 (1995-09-01), pages 4745 - 4753, XP002142068 * |
G. I. SHAPIRO ET AL: "p16INK14a Participates in a G1 arrest Checkpoint in Response to DNA Damage", MOLECULAR AND CELLULAR BIOLOGY, vol. 18, no. 1, January 1998 (1998-01-01), pages 378 - 387, XP002142070 * |
M KUBBUTAT ET AL: "Regulation of p53 stability by mdm2", NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 387, 15 May 1997 (1997-05-15), pages 299 - 303, XP002075660, ISSN: 0028-0836 * |
M. MEYYAPPAN ET AL: "Increased Expression of Cyclin D2 during Multiple States of Growth Arrest in Primary and Established Cells", MOLECULAR AND CELLULAR BIOLOGY, vol. 18, no. 6, June 1998 (1998-06-01), pages 3163 - 3172, XP002142069 * |
T. KIYONO ET AL: "both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells", NATURE, vol. 396, 5 November 1998 (1998-11-05), pages 84 - 88, XP002142067 * |
VAZIRI H ET AL: "ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase", EMBO JOURNAL,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 16, no. 19, 1 October 1997 (1997-10-01), pages 6018 - 6033, XP002118901, ISSN: 0261-4189 * |
XU H -J ET AL: "REEXPRESSION OF THE RETINOBLASTOMA PROTEIN IN TUMOR CELLS INDUCES SENESCENCE AND TELOMERASE INHIBITION", ONCOGENE,GB,BASINGSTOKE, HANTS, vol. 15, no. 21, 1 January 1997 (1997-01-01), pages 2589 - 2596, XP002068735, ISSN: 0950-9232 * |
Also Published As
Publication number | Publication date |
---|---|
WO2000031238A2 (en) | 2000-06-02 |
CA2352486A1 (en) | 2000-06-02 |
IL143328A0 (en) | 2002-04-21 |
EP1133552A2 (en) | 2001-09-19 |
JP2002530436A (en) | 2002-09-17 |
AU2156600A (en) | 2000-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000031238A3 (en) | Methods and reagents for increasing proliferative capacity and preventing replicative senescence | |
WO1999035243A3 (en) | Extension of cellular lifespan, methods and reagents | |
AU4372199A (en) | Electrochemical based assay processes, instrument and labels | |
AU1804300A (en) | Materials for polishing liquid for metal, polishing liquid for metal, method forpreparation thereof and polishing method using the same | |
AU6459998A (en) | An indicator, an associated package and associated methods | |
WO2001085550A3 (en) | Specimen plate lid and method of using | |
AU2001288750A1 (en) | Particle or cell analyzer and method | |
WO2001044516A3 (en) | Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated rna decay | |
WO2003048300A3 (en) | Methods of identifying cellular target molecules | |
AU1913400A (en) | Tapered shank rivet | |
AU3935599A (en) | Method for amplifying at least a particular nucleotide sequence and primers used | |
WO1999055913A3 (en) | Reduced complexity nucleic acid targets and methods of using same | |
HK1037628A1 (en) | Condensed thienopyrimidines with phosphodiesterase-v inhibiting action and the method for preparing the same and use thereof. | |
EP1065213A3 (en) | HCV polymerase suitable for crystal structure analysis and method for using the enzyme | |
ZA972078B (en) | Method and media for enhancing viability, maturation, and cryopreservation of cells. | |
AU4033797A (en) | Surface-treated steel plate for battery case, battery case and battery using the case | |
AU6826900A (en) | Method of determining the activity of 1-deoxy-d-xylulose-5-phosphate reductoisomerase and 1-deoxy-d-xylulose-5-phosphate synthase | |
WO2001066144A3 (en) | Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity | |
WO2000056924A3 (en) | Genomic sequence of the purh gene and purh-related biallelic markers | |
AU2001279525A1 (en) | Secretase/sheddase with asp-ase activity on the beta-site app-cleaving enzyme (bace, asp2, memepsin 2) | |
AU6213600A (en) | Methods for determining the specificity and sensitivity of oligonucleotides for hybridization | |
AU2973799A (en) | Methods for cleaving single-stranded and double-stranded dna substrates with nucleotide integrase | |
AU5617199A (en) | Thermostable (in vitro) complex with polymerase activity | |
AU6059299A (en) | Biological assay compositions containing non-interfering, foam-inhibiting and foam-collapsing agents | |
WO2001026536A3 (en) | Methods of diagnosing and treating hepatic cell proliferative disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 143328 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2352486 Country of ref document: CA Ref country code: CA Ref document number: 2352486 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 584049 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 21566/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999965890 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999965890 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09936035 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999965890 Country of ref document: EP |